1595P QTc-prolonging drug-drug interactions related to CDK4/6 inhibitors

Abstract

The cyclin-dependent kinases (CDK)4/6 inhibitors abemaciclib, palbociclib and ribociclib are approved for the treatment of hormone receptor-positive metastatic breast cancer. These drugs are equally effective according to literature, however, ribociclib is associated with concentration-dependent QTc-prolongation. This complicates ribociclibs use in patients, as pharmacokinetic and pharmacodynamic drug-drug interactions (DDIs) resulting in QTc-prolongation might occur with concomitant medications.